Table 2.
Validation cohort clinical and demographic characteristics.
| n = 26 | |
|---|---|
| Age (mean ± SD) | 70.3 ± 14.1 |
| Female n (%) | 16 (61.5) |
| Baseline NIHSS (mean ± SD) | 8.0 ± 7.1 |
| Partial anterior cerebral infarction n (%) | 11 (42.3) |
| Total anterior cerebral infarction n (%) | 4 (15.4) |
| Lacunar cerebral infarction n (%) | 5 (19.2) |
| Posterior cerebral infarction n (%) | 6 (23.1) |
| Hypertension n (%) | 24 (92.3) |
| Diabetes n (%) | 4 (15.4) |
| Atrial Fibrillation n (%) | 10 (38.5) |
| Myocardial infarction n (%) | 6 (23.1) |
| Dyslipidemia n (%) | 12 (46.2) |
| Hypertension medication n (%) | 22 (84.6) |
| Diabetes medication n (%) | 4 (15.4) |
| Cholesterol medication n (%) | 10 (38.5) |
| Anticoagulant/antiplatelet n (%) | 8 (30.8) |
| rtPA n (%) | 10 (38.5) |
| Current Smoker n (%) | 6 (23.1) |
| Family History of stroke n (%) | 11 (42.3) |
| Previous Stroke n (%) | 6 (23.1) |
SD, standard deviation; NIHSS, National Institutes of Health stroke scale; rtPA, recombinant tissue plasminogen activator.